Stock AKLI AKILI, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Akili, Inc.

Equities

AKLI

US00974B1070

End-of-day quote Nasdaq
Other stock markets
 23:00:00 09/05/2024 BST 		5-day change 1st Jan Change
0.4272 USD -3.87% Intraday chart for Akili, Inc. +6.37% -12.30%
04-30 Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product CI
04-30 Akili, Inc. to Reduce Workforce CI

Evolution of the average Target Price on Akili, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3e9.AkOR5cxVzdLeyFEdgjqXzvHAbyx-7lzmSREyDTr_P38.MS7Ot6oToZ-OqidPtnb6n7yrLEQZrSmIICBkNA2Oaxxgdamq-TOi466FYQ~c9f63a394403ef543cfbe9446c40834a

Analyst Recommendations on Akili, Inc.

Morgan Stanley Adjusts Price Target on Akili to $3 From $2, Maintains Equal-Weight Rating MT
Morgan Stanley Initiates Akili at Equalweight, $2 Price Target, Cites Uncertainties Regarding EndeavorRx's Launch MT
Morgan Stanley Initiates Akili at Equalweight With $2 Price Target MT
BofA Securities Starts Akili at Neutral With $2 Price Target MT
Credit Suisse Starts Akili at Outperform With $5 Price Target MT
Cowen Initiates Coverage on Akili With Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.4272 USD
Average target price
0.65 USD
Spread / Average Target
+52.15%
High Price Target
0.65 USD
Spread / Highest target
+52.15%
Low Price Target
0.65 USD
Spread / Lowest Target
+52.15%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Akili, Inc.

Morgan Stanley
BofA Securities
Credit Suisse
Cowen

Ratings for Akili, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. AKLI Stock
  4. Consensus Akili, Inc.